Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is a healthcare service provider focused on developing drugs for metabolic and endocrine disorders, with a diverse clinical program pipeline consisting of VK2809, VK5211, and VK0214 products. The company's lead asset, VK2735, is a dual GLP-1/GIP peptide agonist with two formulations: daily oral (Phase 2 ongoing) and weekly subcutaneous (Phase 3-ready). Viking is also developing DACRA compounds for obesity, and management's discussion of competitive dynamics and potential partnerships in employer-based models and ex-U.S. markets increases strategic optionality and supports adoption. Additionally, strong cash runway through key value-driving milestones, including Phase 3 development and potential benefits beyond weight loss for VK2735, positions Viking for long-term success.

Bears say

Viking Therapeutics is an established drug development company that faces potential risks and uncertainties in its clinical trials and the competitive commercial market. While it has shown promise in its clinical program pipeline, there is no guarantee that the company's products will be successful or that it will be able to secure adequate funding. Additionally, our valuation and assumptions for the commercial potential of Viking's products contribute to our negative outlook on the stock.

Viking Therapeutics (VKTX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Viking Therapeutics (VKTX) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.